Geoffrey Sonn, MD, presented “Focal Therapy Patient Selection: Urologist Perspective” at the 8th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on October 8, 2024.
How to cite: Sonn, Geoffrey. “Focal Therapy Patient Selection: Urologist Perspective” October 2024. Accessed Apr 2026. https://grandroundsinurology.com/focal-therapy-patient-selection-urologist-perspective/
Focal Therapy Patient Selection: Urologist Perspective – Summary
Geoffrey Sonn, MD, provides a compelling 7-minute presentation on patient selection for focal therapy, emphasizing a urologist’s perspective.
Dr. Sonn shares the criteria for the optimal candidate as a healthy individual with at least a 10-year life expectancy and grade group 2 prostate cancer. Imaging, especially high-quality prostate MRI and PSMA PET, plays a pivotal role, with biopsy confirmation ensuring consistency between imaging findings and pathology. However, he notes that such straightforward cases are rare in practice.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Geoffrey Sonn, MD, is an Associate Professor of Urology at Stanford University in California. Dr. Sonn’s research interests include cancer imaging, MRI-Ultrasound fusion targeted prostate biopsy, prostate cancer focal therapy, robotic surgery for prostate and kidney cancer, and developing artificial intelligence methods to improve prostate cancer detection on MRI and ultrasound. He was the Stanford principal investigator of a major clinical trial using MRI-guided focused ultrasound to treat prostate cancer.
